CD300A and peritonitis: In mouse models of acute and chronic airway AI, passive cutaneous anaphylaxis, and stem cell factor-induced peritonitis models, administration of bispecific anti-CD300a/anti-IgE, anti-CD300a/anti-CCR3, or anti-CD300a/anti-cKit anti-bodies, synthesized to specifically activate this IR on MCs or on Eos, was shown to inhibit several markers of AI [3–5].